JOP20180017A1 - Apoptosis signal-regulating kinase inhibitor - Google Patents

Apoptosis signal-regulating kinase inhibitor

Info

Publication number
JOP20180017A1
JOP20180017A1 JOP/2018/0017A JOP20180017A JOP20180017A1 JO P20180017 A1 JOP20180017 A1 JO P20180017A1 JO P20180017 A JOP20180017 A JO P20180017A JO P20180017 A1 JOP20180017 A1 JO P20180017A1
Authority
JO
Jordan
Prior art keywords
kinase inhibitor
apoptosis signal
regulating kinase
compound
formula
Prior art date
Application number
JOP/2018/0017A
Other languages
Arabic (ar)
Inventor
Kassibla Elodie Dempah
Julie Farand
Gregory Notte
Jennifer Lynne Alleva
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of JOP20180017A1 publication Critical patent/JOP20180017A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Provided is a compound of Formula (I) (I); or a pharmaceutically acceptable salt thereof for use in treatment of non-alcoholic steatohepatitis, alcoholic hepatitis, pulmonary arterial hypertension, heart failure with preserved ejection fraction, and diabetic kidney disease. Also provided are amorphous and crystalline forms of the compound of Formula (I) and salts, co-crystals, solvates, and hydrates thereof.
JOP/2018/0017A 2017-03-14 2017-03-14 Apoptosis signal-regulating kinase inhibitor JOP20180017A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762471300P 2017-03-14 2017-03-14

Publications (1)

Publication Number Publication Date
JOP20180017A1 true JOP20180017A1 (en) 2019-01-30

Family

ID=61750538

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0017A JOP20180017A1 (en) 2017-03-14 2017-03-14 Apoptosis signal-regulating kinase inhibitor

Country Status (6)

Country Link
AR (1) AR111178A1 (en)
BR (1) BR102018004862A2 (en)
JO (1) JOP20180017A1 (en)
TW (1) TW201840551A (en)
UY (1) UY37631A (en)
WO (1) WO2018169742A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (en) 2009-07-13 2015-07-11 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
WO2018209354A1 (en) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
BR112020022114A2 (en) 2018-05-02 2021-01-26 Enanta Pharmaceuticals, Inc. tetrazole containing kinase-1 inhibitors regulating apoptosis signal and methods of using it
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110818683B (en) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2023125904A1 (en) * 2021-12-30 2023-07-06 苏州晶云药物科技股份有限公司 Crystal form of azacyclobutyl nicotinic acid compound and preparation method therefor
CN117503932A (en) * 2022-07-30 2024-02-06 中国医学科学院阜外医院 Use of Jun inhibitors for the preparation of a medicament for the treatment of heart failure with retained ejection fraction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (en) 2009-07-13 2015-07-11 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
UY34573A (en) 2012-01-27 2013-06-28 Gilead Sciences Inc QUINASE INHIBITOR REGULATING THE APOPTOSIS SIGNAL
US20150342943A1 (en) 2014-06-03 2015-12-03 Gilead Sciences, Inc. Methods of treating liver disease
TW201618781A (en) 2014-08-13 2016-06-01 吉李德科學股份有限公司 Methods of treating pulmonary hypertension
MA41252A (en) * 2014-12-23 2017-10-31 Gilead Sciences Inc SOLID FORMS OF AN ASK 1 INHIBITOR

Also Published As

Publication number Publication date
WO2018169742A1 (en) 2018-09-20
UY37631A (en) 2018-09-28
TW201840551A (en) 2018-11-16
AR111178A1 (en) 2019-06-12
BR102018004862A2 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
JOP20180017A1 (en) Apoptosis signal-regulating kinase inhibitor
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA201991693A1 (en) PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND METHOD FOR PRODUCING AND USE
AR106237A2 (en) HETEROCYCLIC INHIBITORS OF ASPARTIL PROTEASA, ITS PHARMACEUTICALLY ACCEPTABLE SALTS
MX2022014414A (en) Pyrimidinedione compounds against cardiac conditions.
EA201691401A1 (en) INDASOLIC COMPOUNDS AS IRAK4 INHIBITORS
CY1118721T1 (en) DERYDRO-1H-INDEN-1-YL-2,7-DIAZASPIER PRODUCT 2,3-DYN-1H-2,7-DIAZAPEIRO AND USE THEM AS COMPETITORS OR REVERSE COMPONENTS
NZ758345A (en) Ask1 inhibitor compounds and uses thereof
PE20140630A1 (en) BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
EA201591291A1 (en) DERIVATIVES OF PYRIMIDON AND THEIR APPLICATION IN TREATMENT, FACILITATION OR PREVENTION OF VIRAL DISEASE
MA38078A1 (en) Pyridine derivative
NO20076450L (en) Heterocyclic compounds as nicotinic acid receptor agonists for the treatment of dyslipidemia
RS54030B1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
EA200802329A1 (en) TRIAZOLE DERIVATIVES II
MX2020011845A (en) Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino]acetic acid.
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel
EA201000362A1 (en) 1,3-DIHYDROIZOINDOL DERIVATIVES
AR124688A2 (en) A PYRIMIDINE SULFONAMIDE OR A TAUTOMER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
AU2020235187A8 (en) Uses of phosphodiesterase inhibitors
PH12021550449A1 (en) 2,6-diamino pyridine compounds.
EP4249005A3 (en) 18f-labeled triazole containing psma inhibitors
CO6361939A2 (en) 5- (2- {[6- (2, 2-DIFLUORO-2-PHENYLETOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYQUINOLIN-2 (IH) -ONA FOR PULMONARY TREATMENT
RU2017121002A (en) CD38 inhibitors and methods of treatment